Y-mAbs Therapeutics Inc
NASDAQ:YMAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.54
18.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
Accrued Liabilities
Y-mAbs Therapeutics Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
Accrued Liabilities
$17.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
22%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
24%
|
|
Y-mAbs Therapeutics Inc
Glance View
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 148 full-time employees. The company went IPO on 2018-09-21. The company is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. The company also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The firm is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.
See Also
What is Y-mAbs Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
17.4m
USD
Based on the financial report for Sep 30, 2024, Y-mAbs Therapeutics Inc's Accrued Liabilities amounts to 17.4m USD.
What is Y-mAbs Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
22%
Over the last year, the Accrued Liabilities growth was 23%. The average annual Accrued Liabilities growth rates for Y-mAbs Therapeutics Inc have been 7% over the past three years , 22% over the past five years .
You don't have any saved screeners yet
